Morning Watchlist

    3 Best Obesity Stocks for 2025 - 3/10

    Ian Cooper
    Monday, March 10, 20255 min read
    3 Best Obesity Stocks for 2025 - 3/10

    *Today's Featured Stock: The Future of Air Travel Is Unfolding—Unlock the name and symbol right here.

    It’s time to buy down, but not out obesity stocks, we said just weeks ago.

    With more drug trial data expected, related stocks could rocket even higher – especially with obesity rates still bursting at the seams. At the moment, according to the U.S. Centers for Disease Control and Prevention, “Blockbuster growth in weight-loss drugs was the main driver of a 13.5% increase in spending on prescription medications in the U.S. in 2023, according to ASHP's (American Society of Health-System Pharmacists) report,” as noted by the American Society of Health-System Pharmacists.

    Viking Therapeutics (SYM: VKTX)

    said that pending FDA feedback from a meeting this year, VK2735, a dual GLP-1/GIP receptor agonist similar to Eli Lilly's blockbuster weight loss drug Zepbound, is still on track to reach late-stage development.

    Helping, analysts at B. Riley says VKTX’s VK2735 has “long-term disruptive potential,” as quoted by Seeking Alpha. The firm added, that

    Yet Kinross Gold just committed over half a million dollars to explore a Nevada gold site owned by a $20 million junior company. If results are good, they agreed to pay more...for 80% of the finds.

    What's so special about this project? And why is an industry leader taking notice?

    Altimmune (SYM: ALT)
    “The phase 3 program will encompass four randomized, double-blind, placebo-controlled trials lasting 60 weeks and enroll a total of 5,000 participants. Three dosage strengths will be tested -- 1.2 mg, 1.8 mg, and 2.4 mg -- and the company said it is aiming for approval of all strengths,” noted Seeking Alpha.

    “With what we estimate as a large potential opportunity for pemvidutide in obesity and MASH combined and ALT at a roughly $508M cap, we think ALT is undervalued.”

    The Oxford Club

    This industry set to BOOM in Trump’s first year



    Structure Therapeutics (SYM: GPCR)
    * We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of Surf Air Mobility (NYSE:SRFM). The compensation consists of $6,000 and was received/will be received from Market Jar Media. This compensation should not be considered as an endorsement of the securities of adviser Surf Air Mobility (NYSE:SRFM) and we are not responsible for any errors or omissions in any information provided about the securities of Surf Air Mobility (NYSE:SRFM). We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 03/10/2025.

    Found this helpful? Share it with others.

    Written by Ian Cooper

    Our Flagship Publication

    Discover Great Companies Trading at a Discount

    Join Behind the Markets